

JosÃ© Luis Izquierdo Alonso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2400620/publications.pdf>

Version: 2024-02-01

58
papers

3,420
citations

172457

29
h-index

138484

58
g-index

71
all docs

71
docs citations

71
times ranked

3170
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining the Heterogeneity of Sleep Apnea Syndrome: A Cluster Analysis With Implications for Patient Management. Archivos De Bronconeumologia, 2022, 58, 125-134.	0.8	12
2	The 7 Cardinal Sins of COPD in Spain. Archivos De Bronconeumologia, 2022, 58, 498-503.	0.8	0
3	Use of N-Acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19. Science Progress, 2022, 105, 003685042210745.	1.9	29
4	Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain. International Journal of COPD, 2022, Volume 17, 245-258.	2.3	5
5	Findings and Prognostic Value of Lung Ultrasound in <sc>COVID</sc>â€19 Pneumonia. Journal of Ultrasound in Medicine, 2021, 40, 1315-1324.	1.7	26
6	The impact of COVID-19 on patients with asthma. European Respiratory Journal, 2021, 57, 2003142.	6.7	164
7	Authorsâ€™ Reply to: Minimizing Selection and Classification Biases Comment on â€œClinical Characteristics and Prognostic Factors for Intensive Care Unit Admission of Patients With COVID-19: Retrospective Study Using Machine Learning and Natural Language Processingâ€. Journal of Medical Internet Research, 2021, 23, e29405.	4.3	1
8	CÃ¡tedras de Patrocinio. QuÃ© y para quÃ©. Revista De Investigaci3n Y Educaci3n En Ciencias De La Salud (RIECS), 2021, 6, 69-74.	0.0	0
9	Manejo clÃnico de la EPOC en situaci3n de vida real. AnÃlisis a partir de big data. Archivos De Bronconeumologia, 2021, 57, 94-100.	0.8	38
10	Characteristics and Prognosis of COVID-19 in Patients with COPD. Journal of Clinical Medicine, 2020, 9, 3259.	2.4	51
11	<p>Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective</p>. International Journal of COPD, 2020, Volume 15, 1621-1632.	2.3	13
12	Clinical Characteristics and Prognostic Factors for Intensive Care Unit Admission of Patients With COVID-19: Retrospective Study Using Machine Learning and Natural Language Processing. Journal of Medical Internet Research, 2020, 22, e21801.	4.3	97
13	Paciente exacerbador con enfermedad pulmonar obstructiva cr3nica: recomendaciones en procesos diagn3sticos, terap3uticos y asistenciales. Archivos De Bronconeumologia, 2019, 55, 478-487.	0.8	16
14	The dose of inhaled corticosteroids in patients with COPD: when less is better. International Journal of COPD, 2018, Volume 13, 3539-3547.	2.3	34
15	Characteristics of COPD Patients Managed in Respiratory Medicine Departments in Spain, According to GOLD Groups and GesEPOC Clinical Phenotypes. Archivos De Bronconeumologia, 2018, 54, 559-567.	0.8	3
16	Mixed Th2 and non-Th2 inflammatory pattern in the asthma–COPD overlap: a network approach. International Journal of COPD, 2018, Volume 13, 591-601.	2.3	44
17	CaracterÃsticas de los pacientes con EPOC tratados en neumologÃa en EspaÃ±a segÃn grupos GOLD y fenotipos clÃnicos GesEPOC. Archivos De Bronconeumologia, 2018, 54, 559-567.	0.8	22
18	Th-2 signature in chronic airway diseases: towards the extinction of asthmaâˆ’COPD overlap syndrome?. European Respiratory Journal, 2017, 49, 1602397.	6.7	55

#	ARTICLE	IF	CITATIONS
19	Futuro de los marcadores biológicos en la EPOC. Archivos De Bronconeumología, 2017, 53, 541-542.	0.8	2
20	The variability of respiratory symptoms and associated factors in COPD. Respiratory Medicine, 2017, 129, 165-172.	2.9	24
21	Asthma-COPD overlap is not a homogeneous disorder: further supporting data. Respiratory Research, 2017, 18, 183.	3.6	28
22	The algae names and collection of the Spanish Phycologist Pedro González Guerrero. Anales Del Jardin Botanico De Madrid, 2017, 74, 047.	0.4	0
23	Relevance of dosage in adherence to treatment with long-acting anticholinergics in patients with COPD. International Journal of COPD, 2016, 11, 289.	2.3	17
24	Comorbilidades de la enfermedad pulmonar obstructiva crónica. Archivos De Bronconeumología, 2016, 52, 547-548.	0.8	5
25	Diferencias entre GesEPOC y GOLD. Archivos De Bronconeumología, 2016, 52, 453-454.	0.8	2
26	What pulmonologists think about the asthma–COPD overlap syndrome. International Journal of COPD, 2015, 10, 1321.	2.3	35
27	Looking at the Heart of Patients with Chronic Obstructive Pulmonary Disease. Respiration, 2015, 90, 187-188.	2.6	0
28	Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respiratory Medicine, 2015, 109, 785-802.	2.9	108
29	Impact of COPD in patients with lung cancer and advanced disease treated with chemotherapy and/or tyrosine kinase inhibitors. International Journal of COPD, 2014, 9, 1053.	2.3	34
30	The Role of Vitamin D in Chronic Obstructive Pulmonary Disease, Asthma and Other Respiratory Diseases. Archivos De Bronconeumología, 2014, 50, 179-184.	0.8	22
31	Papel de la vitamina D en enfermedad pulmonar obstructiva crónica, asma y otras enfermedades respiratorias. Archivos De Bronconeumología, 2014, 50, 179-184.	0.8	19
32	Utilidad clínica e impacto económico de la punción transbronquial convencional de adenopatías mediastínicas en el carcinoma broncogénico. Archivos De Bronconeumología, 2013, 49, 41-46.	0.8	7
33	Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case–control study (CONSISTE study). International Journal of COPD, 2012, 7, 679.	2.3	52
34	The Use of the Lower Limit of Normal as a Criterion for COPD Excludes Patients With Increased Morbidity and High Consumption of Health-Care Resources. Archivos De Bronconeumología, 2012, 48, 223-228.	0.8	8
35	Consensus Document on the Overlap Phenotype COPD–Asthma in COPD. Archivos De Bronconeumología, 2012, 48, 331-337.	0.8	176
36	Documento de consenso sobre el fenotipo mixto EPOC-asma en la EPOC. Archivos De Bronconeumología, 2012, 48, 331-337.	0.8	192

#	ARTICLE	IF	CITATIONS
37	Utilización excesiva de corticoides inhalados en la enfermedad pulmonar obstructiva crónica. Archivos De Bronconeumología, 2012, 48, 207-212.	0.8	9
38	Valoración de la EPOC: regreso al futuro. Archivos De Bronconeumología, 2010, 46, 53-55.	0.8	3
39	Lack of association of ischemic heart disease with COPD when taking into account classical cardiovascular risk factors. International Journal of COPD, 2010, 5, 387.	2.3	19
40	Misdiagnosis of patients receiving inhaled therapies in primary care. International Journal of COPD, 2010, 5, 241.	2.3	40
41	Clinical Audit of Patients Admitted to Hospital in Spain due to Exacerbation of COPD (AUDIPOC Study): Method and Organisation. Archivos De Bronconeumología, 2010, 46, 349-357.	0.8	23
42	Study of the burden on patients with chronic obstructive pulmonary disease. International Journal of Clinical Practice, 2009, 63, 87-97.	1.7	42
43	Impact of COPD severity on physical disability and daily living activities: EDIP-EPOC I and EDIP-EPOC II studies. International Journal of Clinical Practice, 2009, 63, 742-750.	1.7	50
44	Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet, The, 2009, 374, 695-703.	13.7	557
45	Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Archivos De Bronconeumología, 2008, 44, 271-281.	0.8	143
46	Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 72-78.	5.7	99
47	Efficacy and safety of roflumilast in the treatment of asthma. Annals of Allergy, Asthma and Immunology, 2006, 96, 679-686.	1.0	82
48	Economic Impact of Pulmonary Drugs on Direct Costs of Stable Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2004, 1, 215-223.	1.6	46
49	Short-term and Long-term Outcomes of Moxifloxacin Compared to Standard Antibiotic Treatment in Acute Exacerbations of Chronic Bronchitis. Chest, 2004, 125, 953-964.	0.8	189
50	Tratamiento farmacológico de la EPOC en dos niveles asistenciales. Grado de adecuación a las normativas recomendadas. Archivos De Bronconeumología, 2003, 39, 195-202.	0.8	31
51	Fiabilidad del diagnóstico de la EPOC en atención primaria y neumología en España. Factores predictivos. Archivos De Bronconeumología, 2003, 39, 203-208.	0.8	42
52	¿Cuál debe ser el papel del neumólogo en el tratamiento quimioterapéutico del cáncer de pulmón?. Archivos De Bronconeumología, 2003, 39, 483-484.	0.8	10
53	Randomized Controlled Trial of Sequential Intravenous (i.v.) and Oral Moxifloxacin Compared with Sequential i.v. and Oral Co-Amoxiclav with or without Clarithromycin in Patients with Community-Acquired Pneumonia Requiring Initial Parenteral Treatment. Antimicrobial Agents and Chemotherapy, 2002, 46, 1746-1754.	3.2	166
54	Defective Natural Killer and Phagocytic Activities in Chronic Obstructive Pulmonary Disease Are Restored by Glycophosphopeptical (Immunoférin). American Journal of Respiratory and Critical Care Medicine, 2001, 163, 1578-1583.	5.6	100

#	ARTICLE	IF	CITATIONS
55	Utility of Transfer Factor to Detect Different Bronchodilator Responses in Patients with Chronic Obstructive Pulmonary Disease. <i>Respiration</i> , 1998, 65, 282-288.	2.6	11
56	Airway dysfunction in patients with Parkinson's disease. <i>Lung</i> , 1994, 172, 47-55.	3.3	69
57	Extent of centrilobular and panacinar emphysema in smokers' lungs: pathological and mechanical implications. <i>European Respiratory Journal</i> , 1994, 7, 664-671.	6.7	70
58	The Length of Time Healthy Subjects and Patients with Chronic Obstructive Pulmonary Disease Are Able to Withstand Maximal Inspiratory Pressure. <i>Respiration</i> , 1991, 58, 301-303.	2.6	1